Crossmark

The Heidelberg cardio-oncology unit (COUNT)—a possible blueprint for improved care of cardio-oncological patients

Published Online: 2021-06-28

Published Print: 2022-02

Authors

Lehmann, L. H. https://orcid.org/0000-0001-5077-8580
Stein, F.

Jäger, D.

Frey, N.
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (LE3570/2-1)

Deutsche Forschungsgemeinschaft (LE 3570/3-1)

Bundesministerium für Bildung und Forschung (01KC2006B)

Universitätsklinikum Heidelberg
License Information

Text and Data Mining valid from 2021-06-28

Version of Record valid from 2021-06-28
More Information

Article History

Received: 31 March 2021

Accepted: 8 June 2021

First Online: 28 June 2021

Declarations

:

: LHL has served on the advisory board for Daiichi Sankyio, Senaca, and Servier, as an external expert for Astra Zeneca and received speakers’ honoraria from Novartis and MSD.

Document is current